EXPLANATORY STATEMENT
INSTRUMENT NUMBER PB 70 OF 2007
NATIONAL HEALTH ACT 1953
AMENDMENT DETERMINATION UNDER SECTION 84AF
Purpose and operation
Part VII of the National Health Act 1953 (the Act) is the legislative basis of the Pharmaceutical Benefits Scheme (PBS) by which the Commonwealth provides reliable, timely, and affordable access to a wide range of medicines for all Australians.
Subsection 85(1) provides that benefits are to be provided by the Commonwealth in accordance with Part VII in respect of pharmaceutical benefits.
Drugs and medicinal preparations to which Part VII applies are declared by the Minister by legislative instrument to be so under subsection 85(2). These are listed drugs as defined in subsection 84(1). Part VII also applies to certain extemporaneously-prepared medicinal preparations as a result of declarations under paragraph 85(2)(b).
The Minister by legislative instrument can determine the form or forms of a listed drug by reference to strength, type of unit, size of unit or otherwise (subsection 85(3)); the manner of administration of the form of the listed drug so determined (subsection 85(5)); and a brand of the pharmaceutical item (defined in subsection 84(1)) that has the listed drug in that form with that manner of administration (subsection 85(6)). These determinations govern (except for certain extemporaneously-prepared pharmaceutical benefits) what constitutes the pharmaceutical benefit (defined in subsection 84(1)) under Part VII of the Act.
Section 84AF empowers the Minister to determine that a person is the responsible person for a brand of a pharmaceutical item. The Minister can do this if the person has notified the Minister that the person is or will be the supplier of the brand of the pharmaceutical item to wholesalers or, if not, to approved pharmacists directly. The brand must be a listed brand (defined in subsection 84(1) as a brand in relation to which a determination under subsection 85(6) is in force), and there can be no determination in force that any other person is the responsible person for the brand of the pharmaceutical item or of any other pharmaceutical item.
A responsible person for a brand of pharmaceutical item has various responsibilities or functions under the Act. These include those in relation to entering into price agreements under section 85AD, compliance with price disclosure requirements under Division 3B, and the requirement to supply certain brands of pharmaceutical item for a specified period under Division 3C.
This instrument determines the responsible persons for the brands of pharmaceutical items set out in Schedule 1 to the instrument. These persons are bodies corporate and are identified in Schedule 1 by their company name and Australian Business Number (ABN). The names of the responsible persons were notified before the commencement of section 84AF as permitted by subsection 84AF(2).
This legislative instrument in giving effect to recommendations of the Pharmaceutical Benefits Advisory Committee (PBAC) amends the determination under section 84AF made by legislative instrument number PB 50 of 2007 which came into effect on 1 August 2007. The amendments are set out in the items of Schedule 1 to the instrument.
This instrument contains a number of changes in terminology to accord with amendments of the Act by the National Health Amendment (Pharmaceutical Benefits Scheme) Act 2007 which came into effect on 1 August 2007.
A provision-by-provision description of the instrument is contained in the Attachment.
This instrument, expressed to commence on 1 October 2007, was made on 6 September 2007.
Consultations
This instrument affects pharmaceutical companies with medicines listed on the PBS. In relation to the introduction of the responsible person measure, pharmaceutical companies have been consulted during both the policy development and implementation phases. This has occurred through meetings with both peak body organisations and individual companies. Information on this measure has been disseminated through peak industry bodies and during regular meetings with a Stakeholder Reference Group. Particular information on the Responsible Person provisions has been provided by letter to those companies to whom the provisions will apply. Under section 84AF the Minister may only determine a person to be the responsible person for a brand of a pharmaceutical item if the person has notified the Minister that the person is or will be the supplier of the brand of the pharmaceutical item. Each of the persons determined in the instrument to be responsible persons has given the required notification to the Minister.
The PBAC is an independent expert body established by section 100A which makes recommendations to the Minister about which drugs and medicinal preparations should be available as pharmaceutical benefits. PBAC members are appointed following nomination by prescribed organisations and associations from consumers, health economists, practising community pharmacists, general practitioners, clinical pharmacologists and specialists, with at least one member selected from each of those interests or professions. Remaining members are persons whom the Minister is satisfied have qualifications and experience in a field relevant to the functions of the PBAC, and that would enable them to contribute meaningfully to the deliberations of the PBAC. When recommending the listing of a medicine on the PBS, the PBAC takes into account the medical conditions for which the medicine has been approved for use in Australia, its clinical effectiveness, safety and cost-effectiveness compared with other treatments.
ATTACHMENT
Paragraph 1: provides that this instrument commences on 1 October 2007.
Paragraph 2: provides that Schedule 1 amends PB 50 of 2007.
Schedule 1: provides for the following amendments:
SCHEDULE 1
Additions
Amisulpride Tablet 100 g (Amisulpride Sandoz)
Tablet 200 g (Amisulpride Sandoz)
Tablet 400 g (Amisulpride Sandoz)
Fluconazole Capsule 100 mg (Fluconazole Winthrop)
Capsule 200 mg (Fluconazole Winthrop)
Insulin Glulisine Injections (human analogue), cartridges, 100 units per mL, 3 mL, 5 (Apidra SoloStar)
Irbesartan with Tablet 300 mg-25 mg (Avapro HCT 300/25, Karvezide 300/25)
Hydrochlorothiazide
Oxaliplatin Solution concentrate for I.V. infusion 200 mg in 40 mL (Eloxatin)
Ramipril Capsule 10 mg (Tryzan 10)
Deletions
Glucose Indicator—Blood Electrode strips, 50 (GlucoMen Sensor)
Insulin Glulisine Injections (human analogue), cartridges, 100 units per mL, 3 mL, 5 (Apidra)
Insulin Neutral with Injection (human) 30 units-70 units per mL, 10 mL (Mixtard 30/70)
Insulin Isophane Injection (human) 50 units-50 units per mL, 10 mL (Mixtard 50/50)
Injections (human), cartridges, 20 units-80 units per mL, 3 mL, 5 (Mixtard 20/80 Penfill 3mL)
Lumiracoxib Tablet 100 mg (Prexige)
Simvastatin Tablet 5 mg (Lipex 5)
Alteration of Responsible Person
From: Altana Pharma Pty Ltd
To: Nycomed Pty Ltd
Alterations of Listed Drug
From: | Aluminium Hydroxide - Dried with Magnesium Hydroxide
|
To: | Aluminium Hydroxide with Magnesium Hydroxide
|
From: | Aluminium Hydroxide - Dried with Magnesium Trisilicate and Magnesium Hydroxide
|
To: | Aluminium Hydroxide with Magnesium Trisilicate and Magnesium Hydroxide
|
Alterations of Form
Bleomycin
| |
From: | Powder for injection containing bleomycin sulfate 15,000 I.U. (with required solvent)
|
To: | Powder for injection containing bleomycin sulfate 15,000 I.U. (with any determined brand of sodium chloride injection as the required solvent)
|
Cefepime
| |
From: | Powder for injection 1 g (as hydrochloride) (with required solvent)
|
To: | Powder for injection 1 g (as hydrochloride) (with any determined brand of sodium chloride injection as the required solvent)
|
|
|
From: | Powder for injection 2 g (as hydrochloride) (with required solvent)
|
To: | Powder for injection 2 g (as hydrochloride) (with any determined brand of sodium chloride injection as the required solvent)
|
Cyclophosphamide
| |
From: | Powder for injection 1 g (anhydrous) (with required solvent)
|
To: | Powder for injection 1 g (anhydrous) (with any determined brand of sodium chloride injection as the required solvent)
|
|
|
From: | Powder for injection 2 g (anhydrous) (with required solvent) |
|
|
To: | Powder for injection 2 g (anhydrous) (with any determined brand of sodium chloride injection as the required solvent)
|
| |
From: | Powder for injection 500 mg (anhydrous) (with required solvent) |
|
|
To: | Powder for injection 500 mg (anhydrous) (with any determined brand of sodium chloride injection as the required solvent)
|
Electrolyte Replacement, Solution
| ||
From: | Electrolyte replacement solution containing sodium chloride 5.26 g, sodium acetate 3.68 g, sodium gluconate 5.02 g, potassium chloride 370 mg and magnesium chloride 300 mg per | |
|
| |
To: | Electrolyte replacement solution containing sodium chloride 5.26 g, sodium acetate 3.68 g, sodium gluconate 5.02 g, potassium chloride 370 mg and magnesium chloride 300 mg per L, 1 L
| |
Esomeprazole and Clarithromycin and Amoxycillin
| ||
From: | Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium trihydrate), 14 tablets clarithromycin 500 mg and 28 capsules amoxycillin | |
|
| |
To: | Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium trihydrate), 14 tablets clarithromycin 500 mg and 28 capsules amoxycillin 500 mg (as trihydrate)
| |
Metoprolol
| ||
From: | Pack containing 15 tablets metoprolol succinate 23.75 mg (controlled release), 15 tablets metoprolol succinate 47.5 mg (controlled release) and 15 tablets metoprolol | |
|
| |
To: | Pack containing 15 tablets metoprolol succinate 23.75 mg (controlled release), 15 tablets metoprolol succinate 47.5 mg (controlled release) and 15 tablets metoprolol succinate 95 mg (controlled release)
| |
Oestradiol and Oestradiol with Norethisterone
| ||
From: | Pack containing 4 transdermal patches 4.33 mg oestradiol (as hemihydrate) and 4 transdermal patches 510 micrograms oestradiol (as hemihydrate) with 4.8 mg norethisterone | |
|
| |
To: | Pack containing 4 transdermal patches 4.33 mg oestradiol (as hemihydrate) and 4 transdermal patches 510 micrograms oestradiol (as hemihydrate) with 4.8 mg norethisterone acetate
| |
| ||
From: | Pack containing 4 transdermal patches 4.33 mg oestradiol (as hemihydrate) and 4 transdermal patches 620 micrograms oestradiol (as hemihydrate) with 2.7 mg norethisterone | |
|
| |
To: | Pack containing 4 transdermal patches 4.33 mg oestradiol (as hemihydrate) and 4 transdermal patches 620 micrograms oestradiol (as hemihydrate) with 2.7 mg norethisterone acetate
| |
Prochlorperazine
| ||
From: | Suppositories 15 mg, equivalent to 25 mg prochlorperazine maleate, 5 | |
|
| |
To: | Suppositories containing prochlorperazine equivalent to 25 mg prochlorperazine maleate, 5
| |
| ||
From: | Suppositories 3 mg, equivalent to 5 mg prochlorperazine maleate, 5 | |
|
| |
To: | Suppositories containing prochlorperazine equivalent to 5 mg prochlorperazine maleate, 5
| |
Sodium Lactate Compound
| ||
From: | I.V. infusion containing approximately 131 mmol sodium (as lactate and chloride), 5 mmol potassium (as chloride), 2 mmol calcium (as chloride), 29 mmol bicarbonate (as | |
|
| |
To: | I.V. infusion containing approximately 131 mmol sodium (as lactate and chloride), 5 mmol potassium (as chloride), 2 mmol calcium (as chloride), 29 mmol bicarbonate (as lactate) and 111 mmol chloride per L, 1 L
| |
Testosterone
| ||
From: | Injection_containing testosterone esters (30 mg testosterone propionate, 60 mg testosterone phenylpropionate, 60 mg testosterone isocaprate, 100 mg testosterone decanoate) in | |
|
| |
To: | Injection containing testosterone esters (30 mg testosterone propionate, 60 mg testosterone phenylpropionate, 60 mg testosterone isocaprate, 100 mg testosterone decanoate) in 1 mL
| |
Ticarcillin with Clavulanic Acid
| ||
From: | Powder for injection containing ticarcillin 3 g (as sodium) with 100 mg clavulanic acid (as potassium clavulanate) (with required solvent) | |
|
| |
To: | Powder for injection containing ticarcillin 3 g (as sodium) with 100 mg clavulanic acid (as potassium clavulanate) (with any determined brand of sodium chloride injection as the required solvent) | |
Alterations of Listed Drug and Form
From: |
| ||
“Alfaré” | Oral powder 400 g | ||
To: |
| ||
Protein hydrolysate formula with medium chain triglycerides
| Oral powder 400 g (Alfaré) | ||
From: |
| ||
Calcium Folinate | Injection equivalent to 50 mg folinic acid in 5 mL | ||
To: |
| ||
Folinic acid | Injection containing calcium folinate equivalent to 50 mg folinic acid in 5 mL
| ||
From: |
| ||
Calcium Folinate | Injection equivalent to 100 mg folinic acid in 10 mL | ||
To: |
| ||
Folinic acid | Injection containing calcium folinate equivalent to 100 mg folinic acid in 10 mL
| ||
From: |
| ||
Calcium Folinate | Injection equivalent to 300 mg folinic acid in 30 mL | ||
To: |
| ||
Folinic acid | Injection containing calcium folinate equivalent to 300 mg folinic acid in 30 mL
| ||
From: |
| ||
Calcium Folinate | Tablet equivalent to 15 mg folinic acid | ||
To: |
| ||
Folinic acid | Tablet containing calcium folinate equivalent to 15 mg folinic acid
| ||
From: |
| ||
“Caprilon” | Oral powder 420 g | ||
To: |
| ||
Triglycerides — medium chain, formula
| Oral powder 420 g (Caprilon) | ||
From: |
| ||
“Carbohydrate Free Mixture” | Oral powder 225 g | ||
To: |
| ||
Milk protein and fat formula with vitamins and minerals — carbohydrate free
| Oral powder 225 g (Carbohydrate Free Mixture) | ||
From: |
| ||
“Dialamine” | Oral powder 200 g | ||
To: |
| ||
Essential amino acids formula with minerals and vitamin C
| Oral powder 200 g (Dialamine) | ||
From: |
| ||
“Digestelact” | Oral powder 900 g | ||
To: |
| ||
Milk powder — lactose modified
| Oral powder 900 g (Digestelact) | ||
From: |
| ||
Diphtheria and Tetanus Vaccine — Adsorbed | Injection 0.5 mL ampoule | ||
To: |
| ||
Diphtheria and tetanus vaccine, adsorbed
| Injection 0.5 mL
| ||
From: |
| ||
Diphtheria and Tetanus Vaccine — Adsorbed (Diluted) | Injection 0.5 mL in pre-filled syringe | ||
To: |
| ||
Diphtheria and tetanus vaccine, adsorbed, diluted for adult use
| Injection 0.5 mL in pre-filled syringe
| ||
From: |
| ||
“Duocal” | Oral powder 400 g | ||
To: |
| ||
Triglycerides, medium chain and long chain with glucose polymer
| Oral powder 400 g (Duocal) | ||
From: |
| ||
“Easiphen” | Oral liquid 250 mL | ||
To: |
| ||
Amino acid formula with vitamins and minerals without phenylalanine
| Oral liquid 250 mL (Easiphen)
| ||
From: |
| ||
“EleCare” | Oral powder 400 g | ||
To: |
| ||
Amino acids — synthetic, Formula
| Oral powder 400 g (EleCare)
| ||
From: |
| ||
“Energivit” | Oral powder 400 g | ||
To: |
| ||
Carbohydrate, fat, vitamins, minerals and trace elements
| Oral powder 400 g (Energivit) | ||
From: |
| ||
“HCU gel” | Sachets containing oral powder 20 g, 30 | ||
To: |
| ||
Amino acid formula with vitamins and minerals without methionine
| Sachets containing oral powder 20 g, 30 (HCU gel) | ||
From: |
| ||
“HCU express” | Sachets containing oral powder 25 g, 30 | ||
To: |
| ||
Amino acid formula with vitamins and minerals without methionine
| Sachets containing oral powder 25 g, 30 (HCU express) | ||
From: |
| ||
“Karicare De-Lact” | Oral powder 900 g | ||
To: |
| ||
Milk powder — lactose free formula
| Oral powder 900 g (Karicare De-Lact) | ||
From: |
| ||
“Ketonex-1” | Oral powder 350 g | ||
To: |
| ||
Amino acid formula with vitamins and minerals without valine, leucine and isoleucine
| Oral powder 350 g (Ketonex-1) | ||
From: |
|
“Ketonex-2” | Oral powder 325 g |
To: |
|
Amino acid formula with vitamins and minerals without valine, leucine and isoleucine
| Oral powder 325 g (Ketonex-2) |
From: |
|
“Kindergen” | Oral powder 400 g |
To: |
|
Whey protein formula supplemented with amino acids, vitamins and minerals, and low in protein, phosphate, potassium and lactose
| Oral powder 400 g (Kindergen) |
From: |
|
“Locasol” | Low calcium compound powder 400 g |
To: |
|
Milk powder — synthetic
| Low calcium oral powder 400 g (Locasol) |
From: |
|
“Lophlex” | Sachets containing oral powder 27.8 g, 30 |
To: |
|
Amino acid formula with vitamins and minerals without phenylalanine
| Sachets containing oral powder 27.8 g, 30 (Lophlex) |
From: |
|
“Lophlex LQ” | Oral liquid 125 mL, 30 |
To: |
|
Amino acid formula with vitamins and minerals without phenylalanine
| Oral liquid 125 mL, 30 (Lophlex LQ) |
From: |
|
“Mapleflex” | Sachets containing oral powder 29 g, 30 |
To: |
|
Amino acid formula with vitamins and minerals without valine, leucine and isoleucine
| Sachets containing oral powder 29 g, 30 (Mapleflex) |
From: |
|
“Metabolic Mineral Mixture” | Oral powder 250 g |
To: |
|
Mineral mixture
| Oral powder 250 g (Metabolic Mineral Mixture) |
From: |
|
“Minaphlex” | Sachets containing oral powder 29 g, 30 |
To: |
|
Amino acid formula with vitamins and minerals without phenylalanine
| Sachets containing oral powder 29 g, 30 (Minaphlex) |
From: |
|
“Monogen” | Oral powder 400 g |
To: |
|
Triglycerides — medium chain, formula
| Oral powder 400 g (Monogen) |
From: |
|
“MSUD AID III” | Oral powder 500 g |
To: |
|
Amino acid formula with vitamins and minerals without valine, leucine and isoleucine
| Oral powder 500 g (MSUD AID III) |
From: |
|
“MSUD Analog” | Oral powder 400 g |
To: |
|
Amino acid formula with vitamins and minerals without valine, leucine and isoleucine
| Oral powder 400 g (MSUD Analog) |
From: |
|
“MSUD Express” | Sachets containing oral powder 25 g, 30 |
To: |
|
Amino acid formula with vitamins and minerals without valine, leucine and isoleucine
| Sachets containing oral powder 25 g, 30 (MSUD Express) |
From: |
|
“MSUD Express Cooler” | Oral liquid 130 mL, 30 |
To: |
|
Amino acid formula with vitamins and minerals without valine, leucine and isoleucine
| Oral liquid 130 mL, 30 (MSUD Express Cooler) |
From: |
|
“MSUD-gel” | Sachets containing oral powder 20 g, 30 |
To: |
|
Amino acid formula with vitamins and minerals without valine, leucine and isoleucine
| Sachets containing oral powder 20 g, 30 (MSUD-gel) |
From: |
|
“MSUD Maxamaid” | Oral powder 500 g |
To: |
|
Amino acid formula with vitamins and minerals without valine, leucine and isoleucine
| Oral powder 500 g (MSUD Maxamaid) |
From: |
|
“MSUD Maxamum” | Oral powder 500 g |
To: |
|
Amino acid formula with vitamins and minerals without valine, leucine and isoleucine
| Oral powder 500 g (MSUD Maxamum) |
From: |
|
“Neocate” | Oral powder 400 g |
To: |
|
Amino acids — synthetic, Formula
| Oral powder 400 g (Neocate) |
From: |
|
“Neocate Advance” | Oral powder 400 g |
To: |
|
Amino acids — synthetic, formula
| Oral powder 400 g (Neocate Advance) |
From: |
|
“Neocate Advance Tropical Flavour” | Oral powder 400 g |
To: |
|
Amino acids — synthetic, formula
| Oral powder 400 g (Neocate Advance Tropical Flavour) |
From: |
|
“Neocate LCP” | Oral powder 400 g |
To: |
|
Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids
| Oral powder 400 g (Neocate LCP) |
From: |
|
“Pepti-Junior” | Oral powder 450 g |
To: |
|
Protein hydrolysate formula with medium chain triglycerides
| Oral powder 450 g (Pepti-Junior) |
From: |
|
“Phenex-2” | Oral powder 325 g |
To: |
|
Amino acid formula with vitamins and minerals without phenylalanine
| Oral powder 325 g (Phenex-2) |
From: |
|
“Phenex-2” | Oral powder 400 g |
To: |
|
Amino acid formula with vitamins and minerals without phenylalanine
| Oral powder 400 g (Phenex-2) |
From: |
|
“Phlexy-10” | Capsules 500 mg, 200 |
To: |
|
Amino acid formula without phenylalanine
| Capsules 500 mg, 200 (Phlexy-10) |
From: |
|
“Phlexy-10” | Tablets 1 g, 75 |
To: |
|
Amino acid formula without phenylalanine
| Tablets 1 g, 75 (Phlexy-10) |
From: |
|
“Phlexy-10” | Bars 42 g, 20 |
To: |
|
Amino acid formula without phenylalanine
| Bars 42 g, 20 (Phlexy-10) |
From: |
|
“Phlexy-10 Drink Mix” | Sachets containing oral powder 20 g, 30 |
To: |
|
Amino acid formula without phenylalanine
| Sachets containing oral powder 20 g, 30 (Phlexy-10 Drink Mix) |
From: |
|
“PK AID II” | Oral powder 250 g |
To: |
|
Amino acid formula without phenylalanine
| Oral powder 250 g (PK AID II) |
From: |
|
“PKU Cooler 10” | Oral liquid 87 mL, 30 |
To: |
|
Amino acid formula with vitamins and minerals without phenylalanine
| Oral liquid 87 mL, 30 (PKU Cooler 10) |
From: |
|
“PKU Cooler 15” | Oral liquid 130 mL, 30 |
To: |
|
Amino acid formula with vitamins and minerals without phenylalanine
| Oral liquid 130 mL, 30 (PKU Cooler 15) |
From: |
|
“PKU Cooler 20” | Oral liquid 174 mL, 30 |
To: |
|
Amino acid formula with vitamins and minerals without phenylalanine
| Oral liquid 174 mL, 30 (PKU Cooler 20) |
From: |
|
“PKU-Express” | Sachets containing oral powder 25 g, 30 |
To: |
|
Amino acid formula with vitamins and minerals without phenylalanine
| Sachets containing oral powder 25 g, 30 (PKU-Express) |
From: |
|
“PKU-gel” | Sachets containing oral powder 20 g, 30 |
To: |
|
Amino acid formula with vitamins and minerals without phenylalanine
| Sachets containing oral powder 20 g, 30 (PKU-gel) |
From: |
|
“Pro-Phree” | Oral powder 400 g |
To: |
|
Carbohydrate, fat, vitamins, minerals and trace elements
| Oral powder 400 g (Pro-Phree) |
From: |
|
“RCF” | Oral liquid 384 mL |
To: |
|
Soy protein and fat formula with vitamins and minerals — carbohydrate free
| Oral liquid 384 mL (RCF) |
From: |
|
“S-26 LF” | Infant formula powder 900 g |
To: |
|
Milk powder — lactose free formula
| Oral powder 900 g (S-26 LF) |
From: |
|
Sodium Alginate with Calcium Carbonate and Sodium Bicarbonate | Oral liquid 1 g-320 mg-534 mg in 20 mL, 500 mL |
To: |
|
Alginic acid with calcium carbonate and sodium bicarbonate
| Oral liquid containing alginic acid as sodium alginate 1 g, calcium carbonate 320 mg and sodium bicarbonate 534 mg in 20 mL, 500 mL |
From: |
|
Triglycerides Oil — Medium Chain | 500 mL |
To: |
|
Triglycerides, medium Chain
| Oil 500 mL (MCT Oil)
|
From: |
|
“TYR gel” | Sachets containing oral powder 20 g, 30 |
To: |
|
Amino acid formula with vitamins and minerals without phenylalanine and tyrosine
| Sachets containing oral powder 20 g, 30 (TYR gel) |
From: |
|
“TYR Express” | Sachets containing oral powder 25 g, 30 |
To: |
|
Amino acid formula with vitamins and minerals without phenylalanine and tyrosine
| Sachets containing oral powder 25 g, 30 (TYR Express) |
From: |
|
“XLYS, LOW TRY Analog” | Oral powder 400 g |
To: |
|
Amino acid formula with vitamins and minerals without lysine and low in tryptophan
| Oral powder 400 g (XLYS, LOW TRY Analog) |
From: |
|
“XLYS, LOW TRY Maxamaid” | Oral powder 500 g |
To: |
|
Amino acid formula with vitamins and minerals without lysine and low in tryptophan
| Oral powder 500 g (XLYS, LOW TRY Maxamaid) |
From: |
|
“XMET Analog” | Oral powder 400 g |
To: |
|
Amino acid formula with vitamins and minerals without methionine
| Oral powder 400 g (XMET Analog) |
From: |
|
“XMET Maxamaid” | Oral powder 500 g |
To: |
|
Amino acid formula with vitamins and minerals without methionine
| Oral powder 500 g (XMET Maxamaid) |
From: |
|
“XMET Maxamum” | Oral powder 500 g |
To: |
|
Amino acid formula with vitamins and minerals without methionine
| Oral powder 500 g (XMET Maxamum) |
From: |
|
“XMTVI Analog” | Oral powder 400 g |
To: |
|
Amino acid formula with vitamins and minerals without methionine, threonine and valine and low in isoleucine
| Oral powder 400 g (XMTVI Analog) |
From: |
|
“XMTVI Asadon” | Oral powder 200 g |
To: |
|
Amino acid formula without methionine, threonine and valine and low in isoleucine
| Oral powder 200 g (XMTVI Asadon) |
From: |
|
“XMTVI Maxamaid” | Oral powder 500 g |
To: |
|
Amino acid formula with vitamins and minerals without methionine, threonine and valine and low in isoleucine
| Oral powder 500 g (XMTVI Maxamaid) |
From: |
|
“XMTVI Maxamum” | Oral powder 500 g |
To: |
|
Amino acid formula with vitamins and minerals without methionine, threonine and valine and low in isoleucine
| Oral powder 500 g (XMTVI Maxamum) |
From: |
|
“XP Analog” | Oral powder 400 g |
To: |
|
Amino acid formula with vitamins and minerals without phenylalanine
| Oral powder 400 g (XP Analog) |
From: |
|
“XP Analog LCP” | Oral powder 400 g |
To: |
|
Amino acid formula with vitamins, minerals and long chain polyunsaturated fatty acids without phenylalanine
| Oral powder 400 g (XP Analog LCP) |
From: |
|
“XPhen, Tyr Analog” | Oral powder 400 g |
To: |
|
Amino acid formula with vitamins and minerals without phenylalanine and tyrosine
| Oral powder 400 g (XPhen, Tyr Analog) |
From: |
|
“XPhen, Tyr Maxamaid” | Oral powder 500 g |
To: |
|
Amino acid formula with vitamins and minerals without phenylalanine and tyrosine
| Oral powder 500 g (XPhen, Tyr Maxamaid) |
From: |
|
“XPhen, Tyr Maxamum” | Oral powder 500 g |
To: |
|
Amino acid formula with vitamins and minerals without phenylalanine and tyrosine
| Oral powder 500 g (XPhen, Tyr Maxamum) |
From: |
|
“XP Maxamaid” | Oral powder 500 g |
To: |
|
Amino acid formula with vitamins and minerals without phenylalanine
| Oral powder 500 g (XP Maxamaid) |
From: |
|
“XP Maxamum” | Oral powder 500 g |
To: |
|
Amino acid formula with vitamins and minerals without phenylalanine
| Oral powder 500 g (XP Maxamum) |
From: |
|
“XP Maxamum” | Sachets containing oral powder 50 g, 30 |
To: |
|
Amino acid formula with vitamins and minerals without phenylalanine
| Sachets containing oral powder 50 g, 30 (XP Maxamum) |
From: |
|
“XPTM Tyrosidon” | Oral powder 500 g |
To: |
|
Amino acid formula without phenylalanine, tyrosine and methionine
| Oral powder 500 g (XPTM Tyrosidon) |